These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9090445

  • 1. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H, Konarski L, Kowalski P, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
    [Abstract] [Full Text] [Related]

  • 2. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
    Batista CK, Mota JM, Souza ML, Leitão BT, Souza MH, Brito GA, Cunha FQ, Ribeiro RA.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):71-7. PubMed ID: 16708234
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice.
    Ribeiro RA, Freitas HC, Campos MC, Santos CC, Figueiredo FC, Brito GA, Cunha FQ.
    J Urol; 2002 May; 167(5):2229-34. PubMed ID: 11956484
    [Abstract] [Full Text] [Related]

  • 4. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
    Lima MV, Ferreira FV, Macedo FY, de Castro Brito GA, Ribeiro RA.
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):643-50. PubMed ID: 16947012
    [Abstract] [Full Text] [Related]

  • 5. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 6. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N, Pohl J.
    IARC Sci Publ; 1986 Jun; (78):269-79. PubMed ID: 3108156
    [Abstract] [Full Text] [Related]

  • 7. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [Abstract] [Full Text] [Related]

  • 8. Protective effect of ketamine against hemorrhagic cystitis in rats receiving ifosfamide.
    Ozguven AA, Yılmaz O, Taneli F, Ulman C, Vatansever S, Onag A.
    Indian J Pharmacol; 2014 Jun; 46(2):147-51. PubMed ID: 24741183
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 10. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Mar; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 11. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.
    Ozcan A, Korkmaz A, Oter S, Coskun O.
    Arch Toxicol; 2005 Aug; 79(8):461-5. PubMed ID: 15800758
    [Abstract] [Full Text] [Related]

  • 12. Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats.
    Vieira MM, Macêdo FY, Filho JN, Costa AC, Cunha AN, Silveira ER, Brito GA, Ribeiro RA.
    Phytother Res; 2004 Feb; 18(2):135-41. PubMed ID: 15022166
    [Abstract] [Full Text] [Related]

  • 13. Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
    Pohl J, Stekar J, Hilgard P.
    Arzneimittelforschung; 1989 Jun; 39(6):704-5. PubMed ID: 2505783
    [Abstract] [Full Text] [Related]

  • 14. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N, Pohl J, Stekar J.
    J Cancer Res Clin Oncol; 1981 Jun; 100(3):311-20. PubMed ID: 6792207
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
    Glazman-Kuśnierczyk H, Matuszyk J, Radzikowski C.
    Immunopharmacol Immunotoxicol; 1992 Jun; 14(4):883-911. PubMed ID: 1294626
    [Abstract] [Full Text] [Related]

  • 16. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Goren MP, McKenna LM, Goodman TL.
    Cancer Chemother Pharmacol; 1997 Jun; 40(5):371-5. PubMed ID: 9272112
    [Abstract] [Full Text] [Related]

  • 17. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G.
    Arzneimittelforschung; 1979 Jun; 29(4):659-61. PubMed ID: 114192
    [Abstract] [Full Text] [Related]

  • 18. Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice.
    Leite CA, Alencar VT, Melo DL, Mota JM, Melo PH, Mourão LT, Wong DV, Magalhães PJ, Santos AA, Brito GA, Lima-Júnior RC, Cunha FQ, Ribeiro RA.
    J Urol; 2015 Dec; 194(6):1777-86. PubMed ID: 26220217
    [Abstract] [Full Text] [Related]

  • 19. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R.
    Cancer Treat Rep; 1979 Mar; 63(3):501-5. PubMed ID: 106965
    [Abstract] [Full Text] [Related]

  • 20. Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
    Vieira MM, Brito GA, Belarmino-Filho JN, Macedo FY, Nery EA, Cunha FQ, Ribeiro RA.
    Int J Urol; 2003 Nov; 10(11):595-602. PubMed ID: 14633084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.